Hannah Goulart, MD

The safe administration of revumenib among pediatric patients broadens the applicability of results seen with the menin inhibitor.

Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.